4568N Stock Chart & Stats
$281.00
$0.00(0.00%)
At close: 4:00 PM EDT
$281.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$281.00 - $429.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$560.95B
Enterprise Value$4.98M
Total Cash (Recent Filing)$449.81B
Total Debt (Recent Filing)$300.48B
Price to Earnings (P/E)20.2
Beta-0.20
Next Earnings
Nov 04, 2026EPS Estimate
4.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)140.41
Shares Outstanding1,862,893,300
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.98
Price to Book (P/B)3.08
Price to Sales (P/S)2.41
P/FCF Ratio-100.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$415.11Price Target Upside47.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)16.7
Revenue Forecast (FY)$247.74B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained top-line growth (RevenueGrowth ~12.6%) indicates durable demand for Daiichi Sankyo’s products and broadening market penetration. Persistent revenue expansion supports investment in R&D and commercialization, helping sustain long-term pipeline funding and offset cyclical pressures.
Conservative Balance SheetLow leverage and growing equity provide financial flexibility to fund R&D, strategic partnerships, and potential M&A without immediate reliance on external financing. This buffer is especially valuable given recent cash-flow weakness, reducing refinancing and liquidity risk over the medium term.
Oncology Focus And Partnership ModelA strong oncology pipeline and ADC programs, plus revenue from partnerships and royalties, create high-margin and recurring potential streams. Collaborations de-risk development costs and can deliver milestone/royalty income that enhances revenue durability and global commercialization reach over time.
Bears Say
Weak Cash GenerationA sharp drop in operating cash flow and consecutive negative free cash flow reduce internal funding for capex, R&D, and dividends. Over 2-6 months this elevates reliance on the balance sheet and partner payments, constraining financial flexibility if cash conversion doesn't normalize.
Margin And Earnings PressureMargin compression and falling net income despite higher sales suggest rising costs or heavier investment that dilute profitability. If margins do not recover, returns on R&D and new assets will be lower, harming sustainable earnings power and ability to generate free cash flow.
Rapid Asset Growth May Be InefficientMaterial asset expansion without commensurate profit improvement raises the risk of lower asset efficiency and depressed ROA/ROIC. With cash conversion weakening, deploying and monetizing new assets effectively is crucial; failure would strain returns and capital allocation over the medium term.
Daiichi Sankyo Company News
4568N FAQ
What was Daiichi Sankyo Company Limited’s price range in the past 12 months?
Daiichi Sankyo Company Limited lowest stock price was $281.00 and its highest was $429.00 in the past 12 months.
What is Daiichi Sankyo Company Limited’s market cap?
Daiichi Sankyo Company Limited’s market cap is $560.95B.
When is Daiichi Sankyo Company Limited’s upcoming earnings report date?
Daiichi Sankyo Company Limited’s upcoming earnings report date is Nov 04, 2026 which is in 96 days.
How were Daiichi Sankyo Company Limited’s earnings last quarter?
Daiichi Sankyo Company Limited released its earnings results on Jul 31, 2026. The company reported $4.077 earnings per share for the quarter, missing the consensus estimate of $4.625 by -$0.548.
Is Daiichi Sankyo Company Limited overvalued?
According to Wall Street analysts Daiichi Sankyo Company Limited’s price is currently Undervalued.
Does Daiichi Sankyo Company Limited pay dividends?
Daiichi Sankyo Company Limited does not currently pay dividends.
What is Daiichi Sankyo Company Limited’s EPS estimate?
Daiichi Sankyo Company Limited’s EPS estimate is 4.14.
How many shares outstanding does Daiichi Sankyo Company Limited have?
Daiichi Sankyo Company Limited has 1,862,893,300 shares outstanding.
What happened to Daiichi Sankyo Company Limited’s price movement after its last earnings report?
Daiichi Sankyo Company Limited reported an EPS of $4.077 in its last earnings report, missing expectations of $4.625. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Daiichi Sankyo Company Limited?
Currently, no hedge funds are holding shares in MX:4568N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Daiichi Sankyo Company Limited
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer's disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.
4568N Company Deck
4568N Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mixture of clear commercial and clinical momentum—notably strong ENHERTU and accelerating DATROWAY sales, major guideline and regulatory wins, significant milestone income, and favorable legal outcomes—counterbalanced by meaningful expense increases (SG&A and R&D), inventory-related charges and one‑off negative items that pressured reported operating profit. Pipeline execution remains active with several upcoming readouts and continued partnership activity, but there are near‑term cost and timing uncertainties (CMO negotiations, trial adjustments, regional generic pressure). Overall, the positives (robust top‑line growth, flagship product expansion, regulatory and legal wins, and upgraded DATROWAY guidance) outweigh the negatives, while management signals a cautious near‑term margin outlook to be addressed in the forthcoming five‑year plan.View all MX:4568N earnings summaries4568N Stock 12 Month Forecast
Average Price Target
$415.11
▲(47.72% Upside)